Q2: Have GLP-1 drugs been linked to serious conditions like pancreatitis or thyroid cancer
As more Phase 3 data becomes available for triple agonist compounds, our understanding of these mechanisms will continue to expand
As GPCR recycling can be controlled by PKA (Vistein and Puthenveedu, 2013), we also wondered whether our observation of reduced PKA signalling despite similar occupancy for lixisenatide versus exendin-4 (Supplementary Figure 1G) might explain their different recycling rates
While its primary focus was device regulatory scope (FDA found the Exer Scan was marketed beyond the limits of its 510(k) exemption), the letter also enumerated major quality system deficiencies lack of design control procedures, no CAPA system, no complaint-handling SOPs, no auditing processes, etc
GLP-1 agonists are being used in combination with basal insulin (Dungan & DeSantis, 2016), although this is not an FDA-approved indication (see rxlist.com) they should not be used as a substitute for basal insulin, as this has been found to result in a decline in glycemic control)(Dungan & DeSantis, 2016) Clinical trials indicate it can reduce HbA1c by ~0.8% Undergoes renal clearance, with dosage reduction needed if creatinine clearance falls to 25 mL/min, while European guidelines recommend a lower eGFR limit of 20 ml/min (Thomas et al, 2023)